NEW YORK (GenomeWeb News) – A consortium of research centers led by the Institute of Cancer Research, London will partner with Illumina to launch a new sequencing-based testing program to analyze genetic mutations in cancer patients, the Wellcome Trust said today.

Funded with £2.7 million ($4.1 million) from the Wellcome Trust, the Mainstreaming Cancer Genetics program will incorporate Illumina's TruSight Cancer panel into clinical care as part of a three-year pilot project.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.